THE MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): DESIGN OF RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF AN ANTI-CD19 MONOCLONAL ANTIBODY IN GENERALIZED MYASTHENIA GRAVIS

被引：0
|
作者：
Nowak, R.
Benatar, M.
Ciafaloni, E.
Howard, J.
Leite, M.
Utsugisawa, K.
Vissing, J.
Wu, Y.
Abuhatzira, L.
Katz, E.
Ratchford, J.
机构：
来源：
MUSCLE & NERVE | 2020年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [1] DESIGN OF THE PLACEBO-CONTROLLED PHASE 3 STUDY OF INEBILIZUMAB, A SELECTIVE CD19+B CELL DEPLETER, IN GENERALIZED MYASTHENIA GRAVIS: THE MINT STUDY
    Rampal, Nishi
    Benatar, Michael
    Ciafaloni, Emma
    Howard, James F., Jr.
    Leite, Maria Isabel
    Utsugisawa, Kimiaki
    Vissing, John
    Rojavin, Mikhail
    Nowak, Richard J.
    MUSCLE & NERVE, 2024, 70 (03) : 546 - 546
  • [2] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY OF INEBILIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (MINT): TOPLINE EFFICACY AND SAFETY FINDINGS
    Nowak, Richard
    Utsugisawa, Kimiaki
    Benatar, Michael
    Ciafaloni, Emma
    Leite, M. Isabel
    Vissing, John
    Tang, Fengming
    Wu, Yanping
    Rojavin, Mikhail
    Rampal, Nishi
    Howard, James, Jr.
    MUSCLE & NERVE, 2024, 70 (03) : 653 - 654
  • [3] Anti-CD19 CART cells for refractory myasthenia gravis
    Haghikia, Aiden
    Hegelmaier, Tobias
    Wolleschak, Denise
    Boettcher, Martin
    Desel, Christiane
    Borie, Dominic
    Motte, Jeremias
    Schett, Georg
    Schroers, Roland
    Gold, Ralf
    Mougiakakos, Dimitrios
    LANCET NEUROLOGY, 2023, 22 (12): : 1104 - 1105
  • [4] OUTCOMES FROM RAISE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 TRIAL OF ZILUCOPLAN IN GENERALIZED MYASTHENIA GRAVIS
    Howard, James F., Jr.
    Genge, Angela
    Hussain, Yessar
    Kaminski, Henry J.
    Mantegazza, Renato
    Utsugisawa, Kimiaki
    Vu, Tuan
    Brock, Melissa
    Boroojerdi, Babak
    Vanderkelen, Mark
    de la Borderie, Guillemette
    Duda, PetraW
    Leite, M. Isabel
    MUSCLE & NERVE, 2022, 65 : S34 - S35
  • [5] A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis
    Pasnoor, Mamatha
    He, Jianghua
    Herbelin, Laura
    Burns, Ted M.
    Nations, Sharon
    Bril, Vera
    Wang, Annabel K.
    Elsheikh, Bakri H.
    Kissel, John T.
    Saperstein, David
    Shaibani, J. Aziz
    Jackson, Carlayne
    Swenson, Andrea
    Howard, James F., Jr.
    Goyal, Namita
    David, William
    Wicklund, Matthew
    Pulley, Michael
    Becker, Mara
    Mozaffar, Tahseen
    Benatar, Michael
    Pazcuzzi, Robert
    Simpson, Ericka
    Rosenfeld, Jeffrey
    Dimachkie, Mazen M.
    Statland, Jeffrey M.
    Barohn, Richard J.
    NEUROLOGY, 2016, 87 (01) : 57 - 64
  • [6] A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
    Howard, James F., Jr.
    Barohn, Richard J.
    Cutter, Gary R.
    Freimer, Miriam
    Juel, Vern C.
    Mozaffar, Tahseen
    Mellion, Michelle L.
    Benatar, Michael G.
    Farrugia, Maria Elena
    Wang, Jing Jing
    Malhotra, Suneil S.
    Kissel, John T.
    MUSCLE & NERVE, 2013, 48 (01) : 76 - 84
  • [7] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF SUBCUTANEOUS BATOCLIMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
    Nowak, Richard J.
    Benatar, Michael
    Breiner, Ari
    Isaacman, Daniel J.
    Bril, Vera
    MUSCLE & NERVE, 2022, 65 : S21 - S21
  • [8] DEMOGRAPHICS AND BASELINE DISEASE CHARACTERISTICS IN THE INEBILIZUMAB, A SELECTIVE CD19+B CELL DEPLETER, GENERALIZED MYASTHENIA GRAVIS REGISTRATIONAL STUDY (MINT)
    Howard, James F., Jr.
    Benatar, Michael
    Ciafaloni, Emma
    Leite, Maria Isabel
    Nowak, Richard J.
    Utsugisawa, Kimiaki
    Vissing, John
    Wu, Yanping
    Rojavin, Mikhail
    Rampal, Nishi
    MUSCLE & NERVE, 2024, 70 (03) : 545 - 545
  • [9] Study design and methodology of the PREVAIL trial: a phase 3, randomized, doubleblind, placebo-controlled study of the safety and efficacy of subcutaneous ALXN1720 in adults with generalized myasthenia gravis
    Howard, James
    Rakhade, Sanjay
    Scholz, Joachim
    Ortiz, Stephan
    Shang, Shulian
    Vu, Tuan
    NEUROLOGY, 2023, 100 (17)
  • [10] Efgartigimod in Myasthenia Gravis: Phase 3 Trial Design
    Howard, J. F., Jr.
    De Haard, H.
    Parys, W.
    Ulrichts, P.
    Guglietta, A.
    Mantegazza, R. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 353 - 353
12345